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Abstract 
Mini review on inv(10)(p12.1q11.2) ACBD5/RET 
in papillary thyroid cancer (PTC). 
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Papillary Thyroid Carcinoma is a malignant tumor 
with papillary sturucture derived from thyroid 
follicular epithelial cells.  
The tumor cells show cytological features including 
overlapping nuclei, nuclear grooves and intranuclear 
cytoplasmic inclusions. 
Clinics and pathology 
Disease 
Papillary thyroid carcinoma 
Epidemiology 
Thyroid cancer is one of the malignancies most 
closely associated with exposure to ionizing 
radiation in humans, such as exposure produced by 
the atomic bombings in Hiroshima and Nagasaki 
(Imaizumi et al., 2006) and by the Chernobyl nuclear 
power plant accident (Kazakov et al., 1992; 
Astakhova et al., 1998). 
ACBD5-RET fusion gene is a chimeric gene formed by 
pericentric inversion of the short and long arms of 
chromosome 10. 
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(A)Low magnification of papillary thyroid carcinoma with ACBD5/RET. (B) The larger magnification of solid/trabecular-like region. 
RERF's statisticians have recently reported that 
about 36% of the PTC cases among those exposed as 
children or adolescents (below 20 years old) were 
estimated to be attributable to radiation exposure, 
which was considerably higher than that of 4% for 
those exposed as adults (above 20 years old) 
(Furukawa et al., 2013).  
Constitutive activation of the mitogen-activated 
protein kinase (MAPK)-signaling pathway-such as 
alterations of RET, NTRK1, BRAF, and RAS genes-
are frequently found in PTC (Gandhi et al., 2010; 
Greco et al., 2010; Xing et al., 2010).  
These gene alterations can be detected in more than 
70% of PTC cases.  
In PTC from A-bomb survivors who were exposed 
to a radiation dose of more than 500 mGy, gene 
rearangements, including RET, NTRK1 and ALK 
genes, were frequently detected (Hamatani et al., 
2008 and 2012). 
Pathology 
This PTC case developed from one A-bomb survivor 
exposed to radiation dose of 1.8 Gy showed 
moderately or well differentiated papillary structure 
with solid/trabecular-like architectures in several 
areas within cancerous regions. 






ACBD5 (acyl-coenzyme A binding domain 
containing 5)is a member of the acyl-Coenzyme A 
binding protein family, known to function in the 
transport and distribution of long chain acyl-
Coenzyme A. This gene may play a role in the 
differentiation of megakaryocytes and formation of 
platelets. Seven spliced variants have been reported 





RET is a tyrosine kinase receptor whose ligands are 
neurotrophic factors of the glial-cell line derived 
neurotrophic factor (GDNF) family, including 
GDNF, neurturin, artemin and persefin.  









ACBD5-RET fusion traanscript was detected in an 
exposed PTC case. Exon 1-12 of ACBD5 gene 
located on 10p12.1 is fused to exon 12-20 of RET 
gene located 10q11.2 by pericentric inversion of 
chromosome 10. 
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A)The scheme of ACBD5, RET and ACBD5-RET gene, and predicted ACBD5-RET fusion cDNA as well as the cDNA sequence 
around the fusion point.Red and blue dotted boxes indicate tyrosine kinase domain and coiled-coil domain. (B)RT-PCR 
confirmation of ACBD5-RET fusion. Lanes 1, 2, and 6, PTC cases without rearranged RET; lanes 3, 5, and 7, those with 
RET/PTC1; lane 4, PTC harboring ACBD5-RET; lane 8, H2O for negative control; lane 9, cell line TPC1 harboring RET/PTC1; 
lane 10, the synthesized nucleotides for positive control of ACBD5-RET plus genomic DNA; lane M, DNA size marker(pUC19-
MspI digest)(Hamatani et al., 2014). 
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Detection 
A 102 bp cDNA fragment of ACBD5-RET 
containing the fusion point was detected by SMART 
RACE method with SMART adaptor-specific 
primer (5'-
AAGCAGTGGTAACAACGCAGAGTA-3') and 





This fusion protein contains the tyrosine kinase 
domain of RET and coiled-coil domain of ACBD5 
even if any variant of ACBD5 is fused to RET, since 
coiled-coil domain of ACBD5 gene is located on 
exon 10. 
Oncogenesis 
Tumorigenicity of ACBD5-RET fusion gene was 
indicated by an in vitro kinase assay and a in vivo 
tumorigenesis assay with nude mice (Hamatani et 
al., 2014). The tumorigenesis induced by ACBD5-
RET fusion gene products would be due to the 
constitutive activation of tyrosine kinase of RET 
gene through the homodimerization of this fusion 
gene followed by the constitutive activation of 
MAPK pathway (Hamatani et al., 2014). 
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